FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SCHWARTZ BRIAN
2. Date of Event Requiring Statement (MM/DD/YYYY)
9/7/2021 

3. Issuer Name and Ticker or Trading Symbol

INFINITY PHARMACEUTICALS, INC. [INFI]
(Last)        (First)        (Middle)

C/O INFINITY PHARMACEUTICALS, INC., 1100 MASSACHUSETTS AVENUE, FLOOR 4
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

CAMBRIDGE, MA 02138      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)  (1)5/15/2030 Common Stock 60000 $0.99 D  
Stock Option (right to buy)  (2)12/22/2030 Common Stock 56250 $2.14 D  

Explanation of Responses:
(1) This option was granted on May 15, 2020. The option agreement provides that the option becomes exercisable in four equal semi-annual installments beginning on October 28, 2020. Pursuant to a resolution approved by the Issuer's Board of Directors on September 1, 2021, all remaining unvested options became exercisable effective as of September 6, 2021.
(2) This option was granted on December 22, 2020. The option agreement provides that the option becomes exercisable in eight equal semi-annual installments beginning on June 22, 2021. Pursuant to a resolution approved by the Issuer's Board of Directors on September 1, 2021, 37,500 unvested options became exercisable effective as of September 6, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
SCHWARTZ BRIAN
C/O INFINITY PHARMACEUTICALS, INC.
1100 MASSACHUSETTS AVENUE, FLOOR 4
CAMBRIDGE, MA 02138
X



Signatures
/s/ Brian Schwartz9/9/2021
**Signature of Reporting PersonDate

Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Infinity Pharmaceuticals Charts.
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Infinity Pharmaceuticals Charts.